Date of Approval: November 15, 2021

UPDATED FREEDOM OF INFORMATION SUMMARY

SUPPLEMENTAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-253

ProstaMate®

(dinoprost tromethamine injection)

Injectable solution

Beef cows, lactating dairy cows, and replacement beef and dairy heifers

Provides for the addition of the following indications and corresponding dosage regimens: for use with gonadorelin injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows; for use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in lactating dairy cows; for use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in suckled beef cows and replacement beef and dairy heifers, advancement of first postpartum estrus in suckled beef cows, and advancement of first pubertal estrus in beef heifers. In addition, this supplement provides revisions to accommodate the added indications and align it with the RLNAD.

Sponsored by:

Bimeda Animal Health Ltd.

Table of Contents

I. GENERAL INFORMATION

A. File Number

ANADA 200-253

B. Sponsor

Bimeda Animal Health Ltd.
1B The Herbert Building
The Park, Carrickmines
Dublin 18, Ireland

Drug Labeler Code: 061133

U.S. Agent Name and Address:
Stephanie Batliner
Bimeda Inc.
One Tower Lane
Suite 2250
Oakbrook Terrace, IL 60181

C. Proprietary Name

ProstaMate®

D. Drug Product Established Name

dinoprost tromethamine injection

E. Pharmacological Category

Prostaglandin

F. Dosage Form

Injectable solution

G. Amount of Active Ingredient

5 mg/mL dinoprost as dinoprost tromethamine

H. How Supplied

90 mL vials

I. Dispensing Status

Prescription (Rx)

J. Dosage Regimen

- **For use with gonadorelin injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows:** Administer 2 to 4 mL gonadorelin injection (100-200 mcg gonadorelin, as

gonadorelin hydrochloride) per cow as an intramuscular injection in a treatment regimen with the following framework:
  - Administer the first dose of gonadorelin injection (2-4 mL) at Day 0
  - Administer ProstaMate® (25 mg dinoprost, as dinoprost tromethamine) by intramuscular injection 6-8 days after the first dose of gonadorelin injection.
  - Administer a second dose of gonadorelin injection (2-4 mL) 30 to 72 hours after the ProstaMate® injection.
  - Perform FTAI 0 to 24 hours after the second dose of gonadorelin injection, or inseminate cows on detected estrus using standard herd practices.
- **For use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for Synchronization of Estrus in Lactating Dairy Cows:**
  - Administer one EAZI-BREED™ CIDR® Cattle Insert per animal and remove 7 days later (for example if administered on a Monday remove the following Monday).
  - Administer 5 mL ProstaMate® at the time of removal of the EAZI-BREED™ CIDR® Cattle Insert.
  - Observe animals for signs of estrus on Days 2 to 5 after removal of the EAZI-BREED™ CIDR® Cattle Insert and inseminate animals found in estrus following normal herd practices.
- **For use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in suckled beef cows and replacement beef and dairy heifers, advancement of first postpartum estrus in suckled beef cows, and advancement of first pubertal estrus in beef heifers:**
  - Administer one EAZI-BREED™ CIDR® Cattle Insert per animal for 7 days (for example, if administered on a Monday remove on the following Monday).
  - Inject 5 mL ProstaMate® (equivalent to 5 mg/mL dinoprost) 1 day prior to EAZI-BREED™ CIDR® Cattle Insert removal, on Day 6 of the 7 day administration period.
  - Observe animals for signs of estrus on Days 1 to 3 after removal of the EAZI-BREED™ CIDR® Cattle Insert and inseminate animals about 12 hours after onset of estrus.

K. Route of Administration

Intramuscular injection

L. Species/Class

Beef cows, lactating dairy cows, and replacement beef and dairy heifers

M. Indications

- For use with gonadorelin injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows
- For use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in lactating dairy cows
- For use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in suckled beef cows and replacement

beef and dairy heifers, advancement of first postpartum estrus in suckled beef cows, and advancement of first pubertal estrus in beef heifers

N. Reference Listed New Animal Drug (RLNAD)

Lutalyse® Injection; dinoprost tromethamine injection; NADA 108-901; Zoetis Inc.

O. Effect of Supplement

This supplement provides for the addition of the following indications and corresponding dosage regimens: for use with gonadorelin injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows; for use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in lactating dairy cows; for use with EAZI-BREED™ CIDR® (progesterone intravaginal insert) Cattle Insert for synchronization of estrus in suckled beef cows and replacement beef and dairy heifers, advancement of first postpartum estrus in suckled beef cows, and advancement of first pubertal estrus in beef heifers. In addition, this supplement provides revisions to accommodate the added indications and align it with the RLNAD.

II. BIOEQUIVALENCE

CVM did not require additional bioequivalence information for this supplemental approval. The FOI Summary for the original approval of ANADA 200-253, dated February 12, 1999, contains a summary of data that demonstrates bioequivalence of the drug for cattle, swine, and mares.

III. HUMAN FOOD SAFETY

CVM did not require human food safety studies for this supplemental approval.

IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to ProstaMate®:

Warnings: Not for human use. Keep out of reach of children. Pregnant women, asthmatics, or persons with bronchial and other respiratory problems should avoid contact with dinoprost tromethamine.

Note: Spills of ProstaMate® on the skin should immediately be washed off with soap and water.

User Safety: Not for human use. Keep out of the reach of children. Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise **extreme caution** when handling this product. In the early stages, women may be unaware of their pregnancies. Dinoprost tromethamine is readily absorbed through the skin and can cause abortion and/or bronchiospasms. Accidental spillage on the skin should be washed off **immediately** with soap and water.

V. AGENCY CONCLUSIONS

The information submitted in support of this supplemental ANADA satisfy the requirements of section 512(c)(2) of the Federal Food, Drug, and Cosmetic Act. The data demonstrate that ProstaMate®, when used according to the label, is safe and effective for the indications listed in Section I.M. above.

Additionally, data demonstrate that residues in food products derived from cattle treated with ProstaMate® will not represent a public health concern when the product is used according to the label.

VI. APPENDIX

January 20, 2022 – Revised Section I.J. to specify "gonadorelin injection" is the established drug name of gonadorelin hydrochloride. "Administer 2 to 4 mL gonadorelin injection (100-200 mcg gonadorelin) per cow as an intramuscular injection in a treatment regimen with the following framework:" was revised to "Administer 2 to 4 mL gonadorelin injection (100-200 mcg gonadorelin, as gonadorelin hydrochloride) per cow as an intramuscular injection in a treatment regimen with the following framework:".